Summit Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Summit Therapeutics stock has a consensus rating of "Buy" and an average price target of $28.42. The average 1-year stock price forecast is 92.42% higher than the current stock price, while the lowest is $7.63 (-48.34%) and the highest is $44.61 (+202.03%).

Price Target: $28.42 (+92.42%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$7.63	$28.42	$32.64	$44.61
Change	-48.34%	+92.42%	+120.99%	+202.03%

Analyst Ratings

The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	11	10	11	9	9
Buy	1	1	1	1	1	1
Hold	3	3	4	4	5	5
Sell	1	1	1	1	2	2
Strong Sell	0	0	0	0	0	0
Total	16	16	16	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Etzer Darout Barclays	Barclays	Hold Maintains $18	Hold	Maintains	$18	+21.87%	Jun 2, 2026
Dara Azar Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $45	Buy	Maintains	$45	+204.67%	Jun 1, 2026
Bradley Canino Guggenheim	Guggenheim	Buy Maintains $40	Buy	Maintains	$40	+170.82%	Jun 1, 2026
Yigal Nochomovitz Citi	Citi	Buy Maintains $40	Buy	Maintains	$40	+170.82%	Jun 1, 2026
Mohit Bansal Wells Fargo	Wells Fargo	Buy Reiterates $30	Buy	Reiterates	$30	+103.11%	Jun 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.28M

Revenue Next Year

56.30M

from 3.28M

1,618.02%

from 3.28M

EPS This Year

-1.10

from -1.43

EPS Next Year

-1.18

from -1.10

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.81M	705.00K	-	-	-	3.28M
Gross Profit	1.81M	705.00K	-	-	-	2.62M
Gross Margin	100.00%	100.00%	-	-	-	80.00%
Operating Income	-86.19M	-63.62M	-88.74M	-210.99M	-1.09B	-862.61M
Net Income	-88.60M	-78.78M	-614.93M	-221.32M	-1.08B	-879.42M
EPS	-	-	-	-	-1.43	-1.10
Free Cash Flow	-38.30M	-319.72M	-221.68M	-88.94M	84.08M	-643.07M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	14.8M
Avg	3.3M
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	5,161.0%
Avg	1,618.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.10
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-